A phase III open-label study to assess safety and efficacy of palonosetron for preventing chemotherapy-induced nausea and vomiting (CINV) in repeated cycles of emetogenic chemotherapy

被引：0
|
作者：
Kenjiro Aogi
Hiroshi Sakai
Hirohisa Yoshizawa
Norikazu Masuda
Nobuyuki Katakami
Yasuhiro Yanagita
Kenichi Inoue
Masaru Kuranami
Mitsuhiro Mizutani
Noriyuki Masuda
机构：
[1] National Hospital Organization Shikoku Cancer Center,Department of Breast Oncology
[2] Saitama Cancer Center,Department of Thoracic Oncology
[3] Niigata University Medical and Dental Hospital,Bioscience Medical Research Center
[4] National Hospital Organization Osaka National Hospital,Department of Surgery
[5] Institute of Biomedical Research and Innovation,Division of Integrated Oncology
[6] Gunma Cancer Center,Department of Breast Oncology
[7] Saitama Cancer Center,Department of Breast Oncology
[8] Kitasato University School of Medicine,Department of Surgery
[9] Aichi Cancer Center Aichi Hospital,Department of Breast Surgery
[10] Kitasato University School of Medicine,Department of Respiratory Medicine
来源：
Supportive Care in Cancer | 2012年 / 20卷
关键词：
Palonosetron; 5-HT; receptor antagonist; Antiemetic; Chemotherapy-induced nausea and vomiting; Highly emetogenic chemotherapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1507 / 1514
页数：7
相关论文
共 50 条
  • [31] A phase II study of palonosetron combined with dexamethasone to prevent nausea and vomiting induced by highly emetogenic chemotherapy
    Maemondo, M.
    Masuda, N.
    Sekine, I.
    Kubota, K.
    Segawa, Y.
    Shibuya, M.
    Imamura, F.
    Katakami, N.
    Hida, T.
    Takeo, S.
    ANNALS OF ONCOLOGY, 2009, 20 (11) : 1860 - 1866
  • [32] Randomized, double-blind, phase III trial of palonosetron versus granisetron in the triplet regimen for preventing chemotherapy-induced nausea and vomiting after highly emetogenic chemotherapy: TRIPLE study
    Suzuki, K.
    Yamanaka, T.
    Hashimoto, H.
    Shimada, Y.
    Arata, K.
    Matsui, R.
    Goto, K.
    Takiguchi, T.
    Ohyanagi, F.
    Kogure, Y.
    Nogami, N.
    Nakao, M.
    Takeda, K.
    Azuma, K.
    Nagase, S.
    Hayashi, T.
    Fujiwara, K.
    Shimada, T.
    Seki, N.
    Yamamoto, N.
    ANNALS OF ONCOLOGY, 2016, 27 (08) : 1601 - 1606
  • [33] Phase IIIb Safety and Efficacy of Intravenous NEPA for Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Patients with Breast Cancer Receiving Initial and Repeat Cycles of Anthracycline and Cyclophosphamide (AC) Chemotherapy
    Schwartzberg, Lee
    Navari, Rudolph
    Clark-Snow, Rebecca
    Arkania, Ekaterine
    Radyukova, Irena
    Patel, Kamal
    Voisin, Daniel
    Rizzi, Giada
    Wickham, Rita
    Gralla, Richard J.
    Aapro, Matti
    Roeland, Eric
    ONCOLOGIST, 2020, 25 (03) : E589 - E597
  • [34] Management of Chemotherapy-Induced Nausea and Vomiting (CINV): A Short Review on the Role of Netupitant-Palonosetron (NEPA)
    Lorusso, Vito
    Russo, Anna
    Giotta, Francesco
    Codega, Paolo
    CORE EVIDENCE, 2020, 15 : 21 - 29
  • [35] The efficacy of triplet antiemetic therapy with 0.75 mg of palonosetron for chemotherapy-induced nausea and vomiting in lung cancer patients receiving highly emetogenic chemotherapy
    Miura, Satoru
    Watanabe, Satoshi
    Sato, Kazuhiro
    Makino, Masato
    Kobayashi, Osamu
    Miyao, Hiromi
    Iwashima, Akira
    Okajima, Masaaki
    Tanaka, Junta
    Tanaka, Hiroshi
    Kagamu, Hiroshi
    Yokoyama, Akira
    Narita, Ichiei
    Yoshizawa, Hirohisa
    SUPPORTIVE CARE IN CANCER, 2013, 21 (09) : 2575 - 2581
  • [36] The efficacy of triplet antiemetic therapy with 0.75 mg of palonosetron for chemotherapy-induced nausea and vomiting in lung cancer patients receiving highly emetogenic chemotherapy
    Satoru Miura
    Satoshi Watanabe
    Kazuhiro Sato
    Masato Makino
    Osamu Kobayashi
    Hiromi Miyao
    Akira Iwashima
    Masaaki Okajima
    Junta Tanaka
    Hiroshi Tanaka
    Hiroshi Kagamu
    Akira Yokoyama
    Ichiei Narita
    Hirohisa Yoshizawa
    Supportive Care in Cancer, 2013, 21 : 2575 - 2581
  • [37] Transdermal granisetron versus palonosetron for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: a multicenter, randomized, open-label, cross-over, active-controlled, and phase IV study
    Seol, Young Mi
    Kim, Hyo Jeong
    Choi, Young Jin
    Lee, Eun Mi
    Kim, Yang Soo
    Oh, Sung Yong
    Koh, Su Jin
    Baek, Jin Ho
    Lee, Won Sik
    Joo, Young Don
    Lee, Hyun Gi
    Yun, Eun Young
    Chung, Joo Seop
    SUPPORTIVE CARE IN CANCER, 2016, 24 (02) : 945 - 952
  • [38] Efficacy and Safety of Thalidomide As a Pre-Medication of Chemotherapy-Induced Nausea and Vomiting (CINV) Following Highly Emetogenic Chemotherapy (HEC): A Systematic Review and Meta-Analysis
    Xie, Jiyi
    Zhang, Cong
    Li, Shijun
    Dai, Rong
    Sullivan, Mitchell A.
    Deng, Bin
    Xu, Qiling
    Wang, Jinglin
    Shi, Chen
    Zhang, Yu
    FRONTIERS IN ONCOLOGY, 2022, 11
  • [39] Transdermal granisetron versus palonosetron for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: a multicenter, randomized, open-label, cross-over, active-controlled, and phase IV study
    Young Mi Seol
    Hyo Jeong Kim
    Young Jin Choi
    Eun Mi Lee
    Yang Soo Kim
    Sung Yong Oh
    Su Jin Koh
    Jin Ho Baek
    Won Sik Lee
    Young Don Joo
    Hyun Gi Lee
    Eun Young Yun
    Joo Seop Chung
    Supportive Care in Cancer, 2016, 24 : 945 - 952
  • [40] Phase II clinical trial of palonosetron combined with tropisetron in preventing chemotherapy-induced nausea and vomiting
    Ma, Yuan
    Su, Lei
    Liu, Liyan
    Xie, Chao
    Zhang, Xia
    Song, Bao
    Cheng, Sensen
    Liu, Jie
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2015, 8 (05): : 7989 - 7994
12345